Literature DB >> 788681

Administration of obidoxime tablets to man. Plasma levels and side reactions.

G A Simon, M S Tirosh, H Edery.   

Abstract

Twenty-four male volunteers were given obidoxime tablets in quantities ranging from 1.84-3.58 g in a single dose, or 7.36 g divided into 4 equal doses. With the lowest dose, average peak plasma level of the drug was 1.9 mug/ml and after the highest single dose it was 5.6 mug/ml, both attained 1.5 h after administration. In the multiple-dosed individuals, plasma levels of the oxime increased gradually following each additional dose, reaching a peak of 3.5 mug/ml after the last dose. Thirteen individuals complained of one or more of the following side effects: pallor, nausea, pyrosis, headache, generalized weakness, sore throat, and paresthesia of the face muscles. Activities of blood cholinesterase, glutamic oxalacetic transaminase, glutamic pyruvic transaminase, as well as hematocrit values, heart rate, and blood pressure were not affected. It is postulated that due to the undesirable side effects, the general use of obidoxime tablets should not be recommended. However, prophylactic oral treatment with obidoxime could be considered for persons at high risk of organophosphate poisoning or when parenteral administration might not be feasible.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788681     DOI: 10.1007/bf00277566

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  15 in total

1.  [RESORPTION AND EXCRETION OF TOXOGONIN FOLLOWING INTRAMUSCULAR INJECTION IN MAN].

Authors:  W D ERDMANN; I BOSSE; P FRANKE
Journal:  Dtsch Med Wochenschr       Date:  1965-08-13       Impact factor: 0.628

2.  Oral prophylaxis for anticholinesterase poisoning.

Authors:  I W COLEMAN; P E LITTLE; G A GRANT
Journal:  Can J Biochem Physiol       Date:  1961-02

3.  Colorimetric method for determination of red blood cell cholinesterase activity in whole blood.

Authors:  J H FLEISHER; E J POPE
Journal:  AMA Arch Ind Hyg Occup Med       Date:  1954-04

4.  Pralidoxime methanesulfonate: plasma levels and pharmacokinetics after oral administration to man.

Authors:  F R Sidell; W A Groff; A Kaminskis
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

5.  [Possible side-effects of antidotal therapy].

Authors:  W Wirth
Journal:  Arch Toxikol       Date:  1968

6.  [Gastrointestinal absorption of the esterase reactivating substance obidoxime and the possibility of facilitating its absorption].

Authors:  W D Erdmann; S Okonek
Journal:  Arch Toxikol       Date:  1969

7.  Drug absorption. II. Effect of fasting on intestinal drug absorption.

Authors:  J T Doluisio; G H Tan; N F Billups; L Diamond
Journal:  J Pharm Sci       Date:  1969-10       Impact factor: 3.534

8.  Feasibility of prophylaxis by oral pralidoxime. Cholinesterase inactivation by organophosphorus pesticides.

Authors:  G E Quinby
Journal:  Arch Environ Health       Date:  1968-06

9.  [PHARMACOLOGIC-TOXICOLOGIC STUDIES WITH THE DICHLORIDE OF BIS-(4-HYDROXYIMINOMETHYL-1-PYRIDINIUM-METHYL)-ETHER, A NEW ESTERASE REACTIVATOR].

Authors:  W D ERDMANN; H ENGELHARD
Journal:  Arzneimittelforschung       Date:  1964-01

10.  [QUATERNARY HYDROXYIMINOMETHYLPYRIDINIUM SALTS. THE DISCHLORIDE OF BIS-(4-HYDROXYIMINOMETHYL-1-PYRIDINIUM-METHYL)-ETHER (LUEH6), A NEW REACTIVATOR OF ACETYLCHOLINESTERASE INHIBITED BY ORGANIC PHOSPHORIC ACID ESTERS].

Authors:  A LUETTRINGHAUS; I HAGEDORN
Journal:  Arzneimittelforschung       Date:  1964-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.